Medscape:AAEM专家呼吁停止滥用阿奇霉素

2014-02-28 daerwen2008 丁香园

1.滥用不止,药无可用 对于许多常见的感染,临床治疗指南不推荐使用某些抗菌药物,特别是大环内酯类的阿奇霉素进行治疗。阿奇霉素的不当使用已导致了广泛的耐药性,并会促使超级细菌的出现。多位急诊医学专家呼吁,不能在所用感染中滥用阿奇霉素。 已经推荐使用窄谱抗菌药物的国家,其耐药率均出现了下降。目前的临床实践指南推荐采取同样的做法以达到相似的效果。 阿奇霉素于1980年研发问世,1991年开始销售,

1.滥用不止,药无可用

对于许多常见的感染,临床治疗指南不推荐使用某些抗菌药物,特别是大环内酯类阿奇霉素进行治疗。阿奇霉素的不当使用已导致了广泛的耐药性,并会促使超级细菌的出现。多位急诊医学专家呼吁,不能在所用感染中滥用阿奇霉素。

已经推荐使用窄谱抗菌药物的国家,其耐药率均出现了下降。目前的临床实践指南推荐采取同样的做法以达到相似的效果。

阿奇霉素于1980年研发问世,1991年开始销售,截至2011年,已成为最常用的处方抗菌药物。目前阿奇霉素的适应症是:慢性肺疾病急性细菌性加重、急性细菌性鼻窦炎、社区获得性肺炎、咽炎、扁桃体炎、非复杂性皮肤和皮肤附属器感染、尿道炎和宫颈炎、生殖器溃疡性疾病等。

阿奇霉素的半衰期长,容易产生耐药,例如产生亚抑菌浓度,使患者成为耐阿奇霉素肺炎球菌的携带者。

2013年,加拿大儿科协会强烈推荐不要将阿奇霉素用于治疗急性咽炎、中耳炎或社区获得性肺炎。该指南不是建议临床医生不考虑使用它,而是建议“一定不能使用”。唯一例外的是一种危及生命的β-内酰胺类过敏和非典型细菌引起的肺炎。

2.可供选择的药物

大环内酯类药物的耐药率正在逐年增加,而阿奇霉素的每个适应症也都可以找到更好的替代治疗药物。

2012年美国传染病学会(IDSA)鼻窦炎临床实践指南推荐:如果鼻窦炎症状严重或恶化、持续超过10天、或有高热流鼻涕至少3天,即应考虑使用抗菌药物,但绝不推荐大环内酯类药物,因为已有约30%的患者对阿奇霉素耐药。

美国儿科学会的急性细菌性鼻窦炎临床实践指南推荐:1-18岁患者使用阿莫西林或阿莫西林+克拉维酸钾治疗,也未推荐大环内酯类药物。

2012年IDSA指南推荐A组链球菌性咽炎的一线治疗用青霉素,大环内酯类只用于对青霉素过敏的患者。在美国,5%-8%A组链球菌对大环内酯类药物耐药。

2011年IDSA临床实践指南推荐:2岁以上小儿细菌性肺炎患者的一线治疗采用阿莫西林或阿莫西林+克拉维酸。二线用药选择也不包括大环内脂类。2岁以下的小儿肺炎80%是由病毒引起,而阿奇霉素没有抗病毒活性,因此也不推荐。

2007年成人社区获得性肺炎诊治专家共识认为,在既往健康且最近未使用过抗生素的成人患者中,可考虑使用强力霉素联合大环内酯类药物。即使在大环内酯类药物滥用被广为关注之前,共识也不推荐单独使用大环内酯类。

近日,降级使用阿奇霉素的新版治疗推荐已经连续出台,尤其是在儿科。但许多医生已经养成了在特定条件下开具特定抗生素的习惯。因此指南推荐在临床上得以实践至少还需1-2年缓冲时间。

3.加强对患者的教育

造成阿奇霉素滥用的部分压力来源于患者,即使是因病毒引起的呼吸道感染前来就诊,一些患者也会坚持要求使用抗菌药物。

发生这种情况时,即使新一代的大环内酯类疗效不佳,医生通常也会开具患者依从性高的阿奇霉素(一天一次,5天一疗程)。对于大多数因普通病毒性感冒前来就诊的患者,抗菌药物所起的唯一效应只是安慰作用。

病毒感染相关的鼻窦炎中,也存在阿奇霉素滥用现象。使用抗菌药治疗的患者中,94%其实症状并没有改变。

无论数据如何,都很难强行说服患者勉强接受非处方药来缓解症状,但医生也只能尽量解释。事实上,患者只有得到了他们自己想要的药物治疗后才会满意。

最简单的解决方案是医疗站点快速检测,以正确地识别并严肃处理违规者。但目前还没有医院积极采用这一技术,因此离目标实现可能还需要很长一段时间。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081129, encodeId=1ca12081129ed, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 27 12:23:00 CST 2014, time=2014-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725574, encodeId=fca91e255743e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 04 02:23:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701502, encodeId=78e31e0150276, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Sat Mar 08 18:23:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897940, encodeId=65b1189e9407f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 21 23:23:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350939, encodeId=84821350939c5, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458540, encodeId=99d4145854024, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606125, encodeId=41601606125b2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081129, encodeId=1ca12081129ed, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 27 12:23:00 CST 2014, time=2014-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725574, encodeId=fca91e255743e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 04 02:23:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701502, encodeId=78e31e0150276, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Sat Mar 08 18:23:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897940, encodeId=65b1189e9407f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 21 23:23:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350939, encodeId=84821350939c5, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458540, encodeId=99d4145854024, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606125, encodeId=41601606125b2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
    2015-02-04 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081129, encodeId=1ca12081129ed, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 27 12:23:00 CST 2014, time=2014-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725574, encodeId=fca91e255743e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 04 02:23:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701502, encodeId=78e31e0150276, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Sat Mar 08 18:23:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897940, encodeId=65b1189e9407f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 21 23:23:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350939, encodeId=84821350939c5, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458540, encodeId=99d4145854024, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606125, encodeId=41601606125b2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
    2014-03-08 zchen
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081129, encodeId=1ca12081129ed, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 27 12:23:00 CST 2014, time=2014-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725574, encodeId=fca91e255743e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 04 02:23:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701502, encodeId=78e31e0150276, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Sat Mar 08 18:23:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897940, encodeId=65b1189e9407f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 21 23:23:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350939, encodeId=84821350939c5, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458540, encodeId=99d4145854024, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606125, encodeId=41601606125b2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
    2014-09-21 smlt2008
  5. [GetPortalCommentsPageByObjectIdResponse(id=2081129, encodeId=1ca12081129ed, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 27 12:23:00 CST 2014, time=2014-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725574, encodeId=fca91e255743e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 04 02:23:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701502, encodeId=78e31e0150276, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Sat Mar 08 18:23:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897940, encodeId=65b1189e9407f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 21 23:23:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350939, encodeId=84821350939c5, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458540, encodeId=99d4145854024, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606125, encodeId=41601606125b2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
    2014-03-02 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=2081129, encodeId=1ca12081129ed, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 27 12:23:00 CST 2014, time=2014-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725574, encodeId=fca91e255743e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 04 02:23:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701502, encodeId=78e31e0150276, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Sat Mar 08 18:23:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897940, encodeId=65b1189e9407f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 21 23:23:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350939, encodeId=84821350939c5, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458540, encodeId=99d4145854024, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606125, encodeId=41601606125b2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2081129, encodeId=1ca12081129ed, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 27 12:23:00 CST 2014, time=2014-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725574, encodeId=fca91e255743e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 04 02:23:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701502, encodeId=78e31e0150276, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Sat Mar 08 18:23:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897940, encodeId=65b1189e9407f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Sep 21 23:23:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350939, encodeId=84821350939c5, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458540, encodeId=99d4145854024, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606125, encodeId=41601606125b2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 02 08:23:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]

相关资讯

NEJM:阿奇霉素(azithromycin)并不增加青年和中老年人患者心血管事件死亡

以前研究认为阿齐霉素对心血管高风险人群,能够增加心血管死亡风险。但是在真实世界人群中缺乏研究。为此,一项大规模真实世界中的人群研究,刚刚发表在本期的新英格兰杂志上。这是一项18-64岁丹麦的国家级的历史队列研究,关联处方登记注册数据库,患者死亡原因,以及在1997至2010年间患者的一般情况等资料。评估了使用阿齐霉素达到110万疗程,与未使用抗生素的人群对照(1:1倾向得分匹配),另外,还与736

NEJM:阿奇霉素与心血管原因死亡风险增加无关

在基线高危患者中,阿奇霉素的使用与心血管原因的死亡危险升高相关。在未经选择的普通人群中,阿奇霉素是否引起同样的危险尚不清楚。丹麦哥本哈根市国家血清研究所流行病学研究科Henrik Svanstr?m博士等人展开了相关研究,他们发现在青年和中年人的普通人群中,阿奇霉素使用与心血管原因死亡危险升高无关。研究成果日前发表于国际权威杂志NEJM在线版。 研究人员以丹麦成年人(年龄18~64岁)为样本进行

AIM:克拉霉素或红霉素升高他汀药物毒性反应风险

  美国一项研究表明,在老年人群中,他汀类与克拉霉素或红霉素同时应用可升高他汀类药物的毒性反应风险。论文发表于《内科学年鉴》[Ann Intern Med 2013;158(12):869]。   此项基于人群的队列研究纳入了年龄大于65岁的他汀类持续应用者,并对同时应用克拉霉素(72591例)或红霉素(3267例)的受试者和同时应用阿奇霉素者(68478例)进行了

Medscape:每周一次的阿奇霉素长期维持治疗可减少儿童慢性呼吸道疾病的急性加重

路透社健康版10月23日纽约消息:根据来自于澳大利亚和新西兰研究者的一份研究报告所示,每周应用一次阿奇霉素,可减少当地儿童非囊性纤维化支气管扩张及慢性化脓性肺疾病的急性加重。上述研究者在《柳叶刀呼吸医学》(The Lancet Respiratory Medicine)九月十七日在线发表的报告中指出:儿童非囊性纤维化支气管扩张及慢性化脓性肺疾病的急性加重期患者,经常会应用抗生素治疗,但对于使用抗生

NEJM述评:阿奇霉素和其他抗菌药的心血管风险

根据IMS健康研究公司数据,2011年全美约4.3千万(约1/8人口)服用过门诊处方药中的大环内脂类抗生素阿奇霉素。鉴于其心血管疾病风险,这一年,我们在美国食品和药物管理局(FDA)重审了阿奇霉素及其他已批准的大环内酯类抗菌药的标签说明,从发表的研究报告及上市后监测报告来看,这种风险已变得相当明显。在重审的基础上,考虑其所致的QT间期延长和与之相关的尖端扭转型室速,FDA批准了对阿奇霉素标签说明的

Ann Intern Med:克拉霉素或红霉素升高他汀药物毒性反应风险

  美国一项研究表明,在老年人群中,他汀类与克拉霉素或红霉素同时应用可升高他汀类药物的毒性反应风险。论文发表于《内科学年鉴》。   此项基于人群的队列研究纳入了年龄大于65岁的他汀类持续应用者,并对同时应用克拉霉素(72591例)或红霉素(3267例)的受试者和同时应用阿奇霉素者(68478例)进行了比较。主要转归为抗生素处方开具30天内因横纹肌溶解而住院治疗。   结果显示,阿托伐他汀(